drugset / Trial / NCT05338099
Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)
Non-randomizedSequentialOpen-labelTreatment
Summary
Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Duchenne Muscular Dystrophy(DMD)
Timeline
- Start
- 2022-01-18
- Primary completion
- 2022-12-28
- Completion
- 2022-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EN001 | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | EN001 | Cell therapy | 2.5e+06 cells/kg | Intravenous |